Open Accessm6A modification–mediated lncRNA TP53TG1 inhibits gastric cancer progression by regulating CIP2A stability
Author(s) -
Fang Deliang,
Ou Xinde,
Sun Kaiyu,
Zhou Xingyu,
Li Youpei,
Shi Peng,
Zhao Zirui,
He Yulong,
Peng Jianjun,
Xu Jianbo
Publication year - 2022
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.15581
Subject(s) - cancer , apoptosis , cancer research , tumor progression , protein kinase b , phosphatase , pi3k/akt/mtor pathway , chemistry , suppressor , metastasis , cell cycle , cancer cell , biology , phosphorylation , microbiology and biotechnology , biochemistry , genetics
Long noncoding RNAs (lncRNAs) are associated with various types of cancer. However, the precise roles of many lncRNAs in tumor progression remain unclear. In this study, we found that the expression of the lncRNA TP53TG1 was downregulated in gastric cancer (GC) and it functioned as a tumor suppressor. In addition, low TP53TG1 expression was significantly associated with poor survival in patients with GC. TP53TG1 inhibited the proliferation, metastasis, and cell cycle progression of GC cells, while it promoted their apoptosis. m6A modification sites are highly abundant on TP53TG1, and demethylase ALKBH5 reduces TP53TG1 stability and downregulates its expression. TP53TG1 interacts with cancerous inhibitor of protein phosphatase 2A (CIP2A) and triggers its ubiquitination‐mediated degradation, resulting in the inhibition of the PI3K/AKT pathway. These results suggest that TP53TG1 plays an important role in inhibiting the progression of GC and provides a crucial target for GC treatment.